WRONETTA CHARLES: Open Payments
NPI 1558424366 · OPELOUSAS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$394 in 24 payments from 8 companies in 2025. Trend: 2023 $982 · 2024 $637 · 2025 $394
Food & beverage: $394
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $150 |
| Alkermes, Inc. | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
Products named: VRAYLAR, ARISTADA, FANAPT, INVEGA SUSTENNA, INGREZZA, UZEDY, COBENFY, ABILIFY ASIMTUFII.
Industry payments across LA — which companies pay providers there.
